NASDAQ:FBIO - Fortress Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.15 -0.10 (-8.00 %) (As of 01/21/2019 01:35 PM ET)Previous Close$1.25Today's Range$1.13 - $1.263852-Week Range$0.49 - $5.54Volume251,090 shsAverage Volume263,252 shsMarket Capitalization$65.18 millionP/E Ratio-0.71Dividend YieldN/ABeta1.66 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.. Receive FBIO News and Ratings via Email Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FBIO Previous Symbol CUSIP21976U10 Webwww.fortressbiotech.com Phone781-652-4500Debt Debt-to-Equity Ratio0.76 Current Ratio2.25 Quick Ratio2.24Price-To-Earnings Trailing P/E Ratio-0.71 Forward P/E Ratio-0.57 P/E GrowthN/A Sales & Book Value Annual Sales$187.58 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$2.38 per share Price / Book0.48Profitability EPS (Most Recent Fiscal Year)($1.61) Net Income$-66,870,000.00 Net Margins-30.52% Return on Equity-68.16% Return on Assets-28.65%Miscellaneous Employees68 Outstanding Shares56,680,000Market Cap$65.18 million OptionableOptionable Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." How were Fortress Biotech's earnings last quarter? Fortress Biotech (NASDAQ:FBIO) released its quarterly earnings data on Friday, November, 9th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.18. The biopharmaceutical company had revenue of $63.69 million for the quarter, compared to the consensus estimate of $64.88 million. Fortress Biotech had a negative return on equity of 68.16% and a negative net margin of 30.52%. View Fortress Biotech's Earnings History. When is Fortress Biotech's next earnings date? Fortress Biotech is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for Fortress Biotech. What price target have analysts set for FBIO? 3 Wall Street analysts have issued twelve-month price targets for Fortress Biotech's stock. Their predictions range from $10.00 to $11.00. On average, they anticipate Fortress Biotech's stock price to reach $10.6667 in the next year. This suggests a possible upside of 827.5% from the stock's current price. View Analyst Price Targets for Fortress Biotech. What is the consensus analysts' recommendation for Fortress Biotech? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech. Has Fortress Biotech been receiving favorable news coverage? News coverage about FBIO stock has been trending positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fortress Biotech earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. Who are some of Fortress Biotech's key competitors? Some companies that are related to Fortress Biotech include Aclaris Therapeutics (ACRS), Savara (SVRA), Verastem (VSTM), Tyme Technologies (TYME), Intec Pharma (NTEC), Adamas Pharmaceuticals (ADMS), Axsome Therapeutics (AXSM), AVEO Pharmaceuticals (AVEO), Acer Therapeutics (ACER), resTORbio (TORC), Aldeyra Therapeutics (ALDX), Seres Therapeutics (MCRB), Dova Pharmaceuticals (DOVA), Magenta Therapeutics (MGTA) and TAIWAN LIPOSOME/S (TLC). Who are Fortress Biotech's key executives? Fortress Biotech's management team includes the folowing people: Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65) How do I buy shares of Fortress Biotech? Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $1.15. How big of a company is Fortress Biotech? Fortress Biotech has a market capitalization of $65.18 million and generates $187.58 million in revenue each year. The biopharmaceutical company earns $-66,870,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe. What is Fortress Biotech's official website? The official website for Fortress Biotech is http://www.fortressbiotech.com. How can I contact Fortress Biotech? Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected] MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 216 (Vote Outperform)Underperform Votes: 184 (Vote Underperform)Total Votes: 400MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is Liquidity?